LifeVantage entered fiscal 2027 with a debt-free balance sheet, a gross margin near 80% and substantial remaining share-repurchase capacity as newly appointed Chief Executive Officer Terrence Moorehead begins an operational reset following a difficult fiscal 2026.
Fourth-quarter revenue was $42.4 million, down 23.1% from $55.1 million in the prior-year period.
Americas revenue declined 24.8%, while Asia/Pacific and Europe revenue decreased 16.9%.
Adjusted EBITDA was $2.7 million compared with $4.8 million, and adjusted diluted EPS declined to $0.11 from $0.17.
Despite the significant revenue pressure, LifeVantage remained profitable.
Quarterly operating income was $1.7 million, while net income reached $1.3 million, or $0.10 per diluted share.
Adjusted operating income was $1.8 million and adjusted net income was $1.4 million.
The company’s high gross-margin structure remains one of its more attractive financial characteristics.
Fourth-quarter gross profit totaled $33 million, representing 78% of revenue.
That was down from 79.9% a year earlier, with LifeVantage attributing the decline to changes in product mix, inventory-obsolescence expense and higher shipping costs.
Operating-cost ratios improved in several areas despite the sales decline.
Commissions and incentives decreased to 41.3% of revenue from 42.1%.
SG&A declined to $13.9 million from $18.7 million, and SG&A as a percentage of revenue improved to 32.7% from 33.9%.
The lower expense ratio reflected reduced variable employee compensation and lower event-related costs.
The balance sheet provides management with flexibility as it works to stabilize the top line.
LifeVantage ended June with $14.9 million of cash and cash equivalents.
The company had no traditional borrowings on its reported balance sheet, supporting management’s description of LifeVantage as debt-free.
Total liabilities were $28.5 million, consisting primarily of operating liabilities and lease obligations, while shareholders’ equity totaled $33.6 million.
The debt-free position is meaningful because it allows the company to pursue a turnaround without the interest burden or refinancing requirements that could constrain a more highly leveraged consumer-products business.
LifeVantage also retains significant capacity to return capital.
During fiscal 2026, the company repurchased approximately 336,000 shares for $2 million.
As of June 30, another $58.5 million remained available under the $60 million repurchase program approved by the board in January.
The size of the remaining authorization is substantial relative to the company’s annual earnings and balance sheet, although actual future repurchases remain at management’s discretion.
LifeVantage is currently choosing not to issue formal fiscal 2027 guidance because of the recent CEO transition.
That makes the company’s strategy under Moorehead more important than a near-term numerical outlook.
Management said its early priorities will include strengthening the LifeVantage brand, developing a more relevant consumer proposition and improving operational execution.
The company is also integrating LoveBiome, which it acquired in October 2025.
Sales from LoveBiome partially offset declining revenue elsewhere during Q4 and fiscal 2026.
The core business still faces meaningful challenges.
Fiscal-year revenue declined 20.1% to $182.6 million from $228.5 million.
Adjusted EBITDA declined to $13.7 million from $22.1 million, while diluted EPS fell to $0.40 from $0.75.
The company’s active account base also contracted, contributing to lower order counts and smaller average orders.
Full-year gross profit was $141.6 million, representing a 77.6% gross margin.
Excluding an inventory-obsolescence allowance tied to the MindBody GLP-1 System, non-GAAP gross margin was even stronger at 78.9%.
That high gross margin creates meaningful operating leverage if LifeVantage can eventually stabilize and return its revenue base to growth.
Because a large portion of incremental sales can translate into gross profit, a successful turnaround in order volumes and customer activity could potentially have an outsized impact on earnings.
For now, the most positive angle is balance-sheet and business-model resilience rather than growth.
LifeVantage remained profitable despite a 23% quarterly sales decline, maintained a 78% gross margin, reduced SG&A by nearly $5 million and enters its new CEO’s tenure without financial debt.
The company also has almost the entire $60 million repurchase authorization still available.
Those factors give the new management team financial flexibility while it works to rebuild customer demand and reposition the product portfolio.
KEY QUOTES:
“With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage.”
“Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence.”
Terrence Moorehead, President and Chief Executive Officer of LifeVantage
